RDY Adds To Generic Portfolio
Dr. Reddy’s Laboratories (NYSE:RDY) has been busy launching generics and the recent U.S. launch of a generic version of Novatis AG’s (NYSE:NVS) over-the-counter (OTC) drug, Prevacid, was the second one in less than a week. The U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for 15 mg formulation of the [...]
Dr. Reddy’s Laboratories (NYSE:RDY) has been busy launching generics and the recent U.S. launch of a generic version of Novatis AG’s (NYSE:NVS) over-the-counter (OTC) drug, Prevacid, was the second one in less than a week. The U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for 15 mg formulation of the generic drug.
Prevacid is approved for the treatment of acid reflux disease and heartburn. According to the data of SymphonyIRI InfoScan Reviews, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards